These 3 Stocks Are a Must When Building Your Dividend Portfolio

NYSE: PFE | Pfizer Inc. News, Ratings, and Charts

PFE – Since the uncertain economic conditions are expected to keep the stock market under pressure, dividend-paying stocks Pfizer (PFE), ICL Group (ICL), and ARC Document Solutions (ARC) could be solid additions to your portfolio for generating a steady income stream. Keep reading….

As the Federal Reserve tries to reduce rising prices by hiking interest rates, borrowing and spending have become costlier for businesses and individuals. “Borrowing costs for homebuyers, car buyers, and credit card borrowers have increased at the fastest pace in decades,” stated chief financial analyst Greg McBride.

As the current situation is not expected to ease anytime soon, investors can take advantage of dividend-paying stocks to protect themselves against high inflation and uncertain market conditions. Investors’ interest in dividend stocks is evident from SPDR S&P Dividend ETF’s (SDY) 6.9% return over the past month.

Therefore, investors looking to build a dividend portfolio must buy fundamentally strong and consistent dividend-paying stocks Pfizer Inc. (PFE), ICL Group Ltd (ICL), and ARC Document Solutions, Inc. (ARC).

Pfizer Inc. (PFE)

PFE discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women’s health, biosimilars, sterile injectable and anti-infective medicines, and oral COVID-19 treatment.

PFE will pay a $0.40 fourth-quarter cash dividend on December 5, 2022. It has a four-year dividend yield of 3.62%. Its current dividend translates to a 3.50% yield. Over the past three years, its dividend has grown at a CAGR of 5.7%.

On October 5, 2022, PFE announced its acquisition of Global Blood Therapeutics, Inc. (GBT). PFE’s Chief Business Innovation Officer and Executive VP, Aamir Malik, said, “With Global Blood Therapeutics’ talent, portfolio, and pipeline now part of Pfizer, we look forward to accelerating innovation and expeditiously bringing multiple potential best-in-class treatments to people living with sickle cell disease.”

For the fiscal second quarter ended July 3, 2022, PFE’s revenues increased 46.8% year-over-year to $27.74 billion. The company’s adjusted net income increased 94% year-over-year to $11.65 billion. Additionally, its adjusted EPS came in at $2.04, representing a 92% increase from the prior-year quarter.

PFE’s EPS for the quarter ended September 30, 2022, is expected to increase 4.5% year-over-year to $1.40. Its revenue for the quarter ending December 31, 2022, is expected to increase 3.7% year-over-year to $24.72 billion.

 It has an impressive earnings surprise history, surpassing the consensus EPS estimates in each of the trailing four quarters. Over the past year, the stock has gained 6.4% to close the last trading session at $45.74.

PFE’s POWR Ratings reflect its solid prospects. The stock has an overall rating of A, equating to a Strong Buy in our proprietary rating system. The POWR Ratings assess stocks by 118 different factors, each with its own weighting.

Within the Medical – Pharmaceuticals industry, it is ranked #9 out of 162 stocks. The company has an A grade for Value and a B for Quality.

Click here to see the additional POWR Ratings of PFE for Growth, Momentum, Stability, and Sentiment.

ICL Group Ltd (ICL)

Headquartered in Tel Aviv, Israel, ICL, together with its subsidiaries, operates as a specialty minerals and chemicals company worldwide. It operates in four segments: Industrial Products, Potash, Phosphate Solutions, and Innovative Ag Solutions (IAS).

Its current dividend translates to a 12.83% yield. It has a four-year dividend yield of 3.6%. Over the past three years, its dividend has grown at a CAGR of 55%.

On August 16, 2022, ICL and Evogene Ltd. (EVGN) announced a multi-year, strategic collaboration agreement between ICL and Lavie Bio Ltd., a subsidiary of Evogene. President of Innovative Ag Solutions for ICL, Mr. Elad Aharonson, believes this collaboration resonates with the company’s sustainability goals and values.

It demonstrates ICL’s commitment to bringing new, sustainable technologies to market for its customers, providing a strong platform to enter the ag-biologicals market.

ICL’s sales increased 78.1% year-over-year to $2.88 billion for the second quarter ended June 30, 2022. The company’s gross profit increased 170% from the year-ago period to $1.54 billion. Its operating income gained 368.7% year-over-year to $1.14 billion, while its adjusted net income attributable increased 456% year-over-year to $751 million.

Also, its adjusted EBITDA increased 249% year-over-year to $1.25 billion. In addition, its EPS came in at $0.44, representing a 300% increase from the prior-year quarter.

ICL’s EPS and revenue for the third quarter ended September 2022, are expected to increase 172.2% and 48.6% year-over-year to $0.45 and $2.66 billion, respectively. It has a commendable earnings surprise history, surpassing the consensus EPS estimates in each of the trailing four quarters. Over the past month, the stock has gained 8.9% to close the last trading session at $9.05.

ICL’s strong fundamentals are reflected in its POWR Ratings. The stock’s overall A rating translates to a Strong Buy in our proprietary rating system. It is ranked #1 in the Agriculture industry. It has an A grade for Growth and a B for Value and Quality.

We have also given ICL grades for Momentum, Stability, and Sentiment. Get all ICL ratings here.

ARC Document Solutions, Inc. (ARC)

ARC, a digital printing company, provides digital printing and document-related services in the United States. It provides managed print services, cloud-based document management software, and other digital hosting services. The company also offers professional and software services to re-produce and distribute documents of different formats and specialized graphic color printing.

ARC has a four-year dividend yield of 1.72%. Its current dividend translates to an 8.2% yield.

For the fiscal second quarter ended June 30, 2022, ARC’s net sales increased 8.4% year-over-year to $74.56 million. The company’s gross profit increased 12% year-over-year to $25.54 million. Its adjusted net income attributable to ARC increased 42.3% year-over-year to $3.70 million.

In addition, its adjusted EPS came in at $0.08, representing a 33.3% increase from the prior-year quarter. Also, its adjusted EBITDA increased 2.3% year-over-year to $11.33 million.

Analysts expect ARC’s EPS for fiscal 2022 to increase 22.7% year-over-year to $0.27. Its revenue for the quarter ending December 31, 2022, is expected to increase 2% year-over-year to $70.60 million. Over the past month, the stock has gained 1.2% to close the last trading session at $2.44.

ARC’s POWR Ratings reflect this positive outlook. The stock has an overall rating of A, translating to a Strong Buy in our proprietary rating system. It is ranked #2 out of 45 stocks in the B-rated Outsourcing – Business Services industry. In addition, it has an A grade for Value, Sentiment, and Quality and a B for Stability.

Click here to see the other ratings of ARC for Growth and Momentum.


PFE shares were trading at $47.43 per share on Friday afternoon, up $1.69 (+3.69%). Year-to-date, PFE has declined -17.77%, versus a -17.17% rise in the benchmark S&P 500 index during the same period.


About the Author: Dipanjan Banchur


Since he was in grade school, Dipanjan was interested in the stock market. This led to him obtaining a master’s degree in Finance and Accounting. Currently, as an investment analyst and financial journalist, Dipanjan has a strong interest in reading and analyzing emerging trends in financial markets. More...


More Resources for the Stocks in this Article

TickerPOWR RatingIndustry RankRank in Industry
PFEGet RatingGet RatingGet Rating
ICLGet RatingGet RatingGet Rating
ARCGet RatingGet RatingGet Rating

Most Popular Stories on StockNews.com


Bullish or Bearish Stock Set Up?

The S&P 500 (SPY) record highs sounds pretty darn bullish on the surface. Yet as we dig below the surface there are some curious signals that point more Risk Off. This is especially true as we come into the next Fed meeting after a round of data that points to inflation still being too high...only further delaying the first rate cut. What does this all mean for stocks from here? Steve Reitmeister offers his latest views on the market outlook along with a preview of his top picks to stay on step ahead of the market. Read on for more...

Unveiling Adobe (ADBE) Q2 Earnings: What Lies Ahead for Investors?

Software giant Adobe Inc. (ADBE) has released its second-quarter earnings, revealing double-digit growth in both revenue and profits. Yet, concerns arise around the complexities of navigating growth in the face of advancing AI technologies. Let’s analyze ADBE’s recent performance and assess key fundamentals to uncover what lies ahead for investors…

3 AI Stocks to Invest in for the Next Technological Revolution

The AI market is experiencing a significant growth trajectory, driven by widespread application across various industries. Hence, it could be wise to invest in top AI stocks, Alphabet (GOOGL), Meta Platforms (META), and Alibaba Group Holding (BABA) for the next technological revolution. Read more...

Analyzing Broadcom’s (AVGO) Q2 Earnings: Worth Investing?

Driven by a surge in demand for its AI products, Broadcom (AVGO) reported robust earnings in its latest quarterly results, exceeding expectations on both top and bottom lines. However, is the stock’s recent announcement of a 10-for-1 stock split worth investing in? Keep reading to find out…

Stock Alert: Breakout or Fake Out?

The S&P 500 (SPY) officially made new highs this week. Perhaps a reason to celebrate more gains on the way...or perhaps there are signs this move is hollow leading to more downside soon on the way. To help solve this riddle, 44 year investment veteran Steve Reitmeister shares his views along with a trading plan and top picks to stay on the right side of the action. That is what Steve Reitmeister will cover in his latest commentary below. Read on for more...

Read More Stories

More Pfizer Inc. (PFE) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All PFE News